Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantification of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jason, Armstrong, Andrew J., Friedlander, Terence W., Kim, Won, Pal, Sumanta K., George, Daniel J., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784676/
https://www.ncbi.nlm.nih.gov/pubmed/29368638
http://dx.doi.org/10.1186/s40425-018-0314-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784676/
https://www.ncbi.nlm.nih.gov/pubmed/29368638
http://dx.doi.org/10.1186/s40425-018-0314-1

Ejemplares similares